Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions

France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.  

Jump start
Expanded collaboration electrifies Innate's US commercial ambitions • Source: Shutterstock.

France's Innate Pharma SA has bounced back from last year's R&D disappointments with an expanded, multi-layered oncology development collaboration with AstraZeneca PLC, which will see the UK-based big pharma gaining rights or access to several promising immuno-oncology candidates from Innate including monalizumab, and Innate Pharma taking a license to AstraZeneca's rare oncology disease product, Lumoxiti (moxetumomab pasudotox-tdfk) to further its own US and EU commercial ambitions.

Investors responded positively to the news, with Innate's Euronext price rising initially by 35% to €6.50 on Oct. 23, 2018,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer